Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05402345 · ClinicalTrials.gov registry record · Phase 2
A Study of GlcNAc on Tear Production in NGLY1-CDDG
A Phase 2 study of NGLY1 Deficiency, sponsored by Eva Morava-Kozicz.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT05402345: Active Phase 2 study of NGLY1 Deficiency, sponsored by Eva Morava-Kozicz.
NCT05402345 is a Phase 2 study of NGLY1 Deficiency that is active but no longer recruiting, run by Eva Morava-Kozicz. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05402345, a Phase 2 study of NGLY1 Deficiency, is active but no longer recruiting, sponsored by Eva Morava-Kozicz.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
Primary Outcome
The primary endpoint of the study is the difference in tear production from baseline in individuals with NGLY1-CDDG between the placebo and the GlcNAc group after 6 weeks of blinded therapy, as measured by Schirmer II test which is a tool that helps assess the amount of tears in the eyes.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG GlcNAc-GlcN
Study Locations (2)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05402345 still lists
NCT05402345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with NGLY1 Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05402345 reports a single indexed study location in Pennsylvania, Washington.
Frequently Asked Questions
What is clinical trial NCT05402345 about?
NCT05402345 is a clinical study titled "A Study of GlcNAc on Tear Production in NGLY1-CDDG". In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
What is the current status of trial NCT05402345?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2025-01-24. Estimated completion is 2026-12.
What conditions does trial NCT05402345 study?
This clinical trial studies the following conditions: NGLY1 Deficiency.
What interventions are being tested in trial NCT05402345?
The interventions under investigation include: Placebo (OTHER), GlcNAc-GlcN (DRUG).
Who is sponsoring clinical trial NCT05402345?
This trial is sponsored by Eva Morava-Kozicz, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05402345 being conducted?
This trial has 2 study locations across Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NGLY1 Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05402345's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI